Istituto Auxologico Italiano   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Milan Italy (1958)

Organization Overview

First Clinical Trial
2000
NCT02048215
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

IRCCS Istituto Auxologico Italiano | Istituto Auxologico Italiano | Istituto Auxologico Italiano IRCCS | Istituto Auxologico Italiano - Milan, Italy | Istituto Auxologico Italiano. Milan. Italy

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Altitude Sickness (Phase 4)

Amyotrophic Lateral Sclerosis (Phase 2)

Apnea (Phase 2)

Cystic Fibrosis (Phase 3)

Diabetes Mellitus (Phase 4)

Fibrosis (Phase 3)

Heart Failure (Phase 4)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Primary (Phase 4)

Hypertension (Phase 4)

Hypoxia (Phase 4)

Motor Neuron Disease (Phase 2)

Obesity (Phase 3)

Osteoporosis (Phase 4)

Sclerosis (Phase 2)

Sleep Apnea, Obstructive (Phase 2)

Sleep Apnea Syndromes (Phase 2)

Weight Loss (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 23